Clínicas Doctor Life, C/ Infantas 32, 28004, Madrid, Spain.
Obes Surg. 2019 Nov;29(11):3443-3447. doi: 10.1007/s11695-019-04014-z.
Obesity is one of the main challenges in the first world nowadays. New alternatives are needed and endoscopic endoluminal approaches are gaining importance against the risky surgery and the non-efficient pharmacological treatments. Nevertheless, these techniques seem to be inefficient in obese III patients. The aim of the study is to demonstrate the safety and efficiency of the new reinforced POSE 18-plication protocol.
Mean body mass index (BMI) ≈ 47 kg/m obese type III patients were treated in different Spanish centers with the new POSE method consisting of 18 plications in the stomach body. On the other hand, 15 lower body mass patients BMI ≈ 40 kg/m were treated with the standard POSE method previously described.
Three months follow-up shows an overall % total weight loss (TWL) and % excess weight loss (EWL) of 15% and 41% respectively for standard POSE and 17% and 36% for the new reinforced POSE18. Both are equally safe and the endpoint weight loss objectives are reached. Endoluminal procedures have been demonstrated to be useful in overweight and obese type I/II. However, bariatric surgery is recommended for higher BMI > 40 kg/m. We successfully applied a non-standard POSE protocol and the patients reached 17%TWL in 3 months.
Our study shows that reinforced POSE 18 can be successfully applied in obese type III; it is safer than bariatric surgery and there are no associated risks when compared with standard endoscopic surgery.
肥胖是当今第一世界面临的主要挑战之一。需要新的替代方案，内镜腔内方法相对于有风险的手术和非有效的药物治疗变得越来越重要。然而，这些技术对于肥胖 III 型患者似乎效果不佳。本研究旨在证明新型强化 POSE 18 折叠术的安全性和有效性。
平均体重指数（BMI）≈47kg/m2 的肥胖 III 型患者在不同的西班牙中心接受新型 POSE 方法治疗，该方法包括胃体的 18 个折叠。另一方面，15 名体重指数（BMI）≈40kg/m2 的低体重患者接受了先前描述的标准 POSE 方法治疗。
3 个月的随访显示，标准 POSE 和新型强化 POSE18 的总体总体重减轻（TWL）和超重减轻百分比（EWL）分别为 15%和 41%，17%和 36%。两种方法均同样安全，达到了终点体重减轻目标。内镜程序已被证明在超重和肥胖 I/II 型患者中有用。然而，对于 BMI>40kg/m2 的患者，建议进行减重手术。我们成功应用了非标准 POSE 方案，患者在 3 个月内达到了 17%的 TWL。
我们的研究表明，强化 POSE 18 可成功应用于肥胖 III 型患者；与减重手术相比，它更安全，与标准内镜手术相比，没有相关风险。
